In 2000, riding the wave of euphoria surrounding the human genome project, the UK's Oxford GlycoSciences PLC raised £150 million ($230 million) in one of the largest secondary offerings the European biotech market had ever seen [See Deal]. Three years on—in very different market circumstances--it was OGS' remaining cash that became central to the European biotech sector's first bidding war. Yet notwithstanding the group's £136 million war chest as of the end of 2002, OGS ultimately sold to UCB Celltech in late April 2003 for only £101.4 million [See Deal].
In current markets, it's not unusual to see biotech companies trading—and being sold—below cash. Yet given the interest in OGS—at one stage, there were as many as seven suitors—this end...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?